Dr. Rosengren presents ten tips for motivational interviewing to help clinicians listen and help their clients struggling with addiction issues.
Read More
At its most basic, motivational interviewing is a conversation in which you are trying to help someone deal with ambivalence that prevents them from acting on a problematic behavior. At a more complex level, it has to do with things like paying attention to how the patient talks and what kind of language they’re using. In this interview, Dr. Rosengren discusses the language and process of motivational interviewing.
Read More
Psilocybin, a naturally occurring and psychedelic compound of the Psilocybe species of mushrooms, has garnered the most attention. Psilocybin is essentially a serotonin 2A agonist. Theoretically, this action should mediate depressive symptoms, but we don’t know for sure because no available antidepressants are direct agonists of this receptor. Researchers from the United Kingdom set out to see if this is indeed the case.
Read More
Both varenicline (Chantix) and bupropion (Zyban) are effective anti-smoking agents, but over the years we’ve heard about potential neuropsychiatric side effects, especially related to varenicline. These include depression, suicidal thoughts, psychosis, and nightmares.
Read More
Dr. Capurso is the Assistant Director of Addiction Services at Connecticut Valley Hospital and an associate clinical professor of psychiatry at the Yale University School of Medicine. Prior to joining Connecticut Valley Hospital, he was the medical director of the Detoxification & Addiction Stabilization Service and the Psychosocial Residential Rehabilitation Program at the West Haven Veterans Administration Hospital. He completed medical school, psychiatry residency, and addiction psychiatry fellowship at Yale.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.webp?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
